ProPhase Labs Overview
ProPhase Labs (PRPH) has a P/E ratio of -0.0, below the Healthcare sector average of 19.01.
Get informed when a big investor buys or sells
+ Follow0.00
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
ProPhase Labs (PRPH) currently reports a P/E ratio of -0.0. That is below the Healthcare sector average of 19.01. Use the charts on this page to explore ProPhase Labs's P/E ratio history and peer comparisons.
ProPhase Labs's P/E ratio of -0.0 is lower than the Healthcare sector average of 19.01. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates ProPhase Labs's market price to a fundamental measure such as earnings, sales, or book value. At -0.0, PRPH can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.01. From there, open related valuation or income-statement pages for ProPhase Labs, and consider following PRPH for alerts when major investors trade the stock.
ProPhase Labs is classified in the Healthcare sector. On P/E ratio, it currently shows -0.0 versus a sector average near 19.01. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRPH with unrelated industries.
